ErVaccine and Centre Leon Berard collaborative project selection by French ANR
September 22, 2022

ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of their research collaborative project (PRCE) grant proposal by French National Research Agency (ANR), for a total amount close to 500k€ of non-dilutive funding in the form of grants. The purpose of the research program is to provide the pre-clinical proof-of-concept of TCR engineered T-cells targeting endogenous retrovirus (HERV) antigens as a new strategy in the treatment of Triple Negative Breast Cancer. This approach would have the advantage of being transferable to other tumors overexpressing HERV antigens.

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact



+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go